

NIA Alzheimer's Disease Centers

Boston, Massachusetts

Richard J. Hodes, M.D.
Director
NIA/NIH/DHHS

October 6, 2012



NIH/NIA Legislative Update



NIH/NIA Budget Update

The President has signed H J Res 117, a 6 month Continuing Resolution to fund the government from October 1, 2012 –March 27, 2013.

Provide stopgap funding in the first half of fiscal 2013, with spending for discretionary programs set at the \$1.047 trillion.

National Plan to Address Alzheimer's Disease

<http://aspe.hhs.gov/daltcp/napa/NatIPlan.pdf>



U.S. Department of Health and Human Services
Office of Assistant Secretary for Planning and Evaluation

NIH Alzheimer's Disease Funding

	AD Research in 2011	% AD	Total Funding
NIA	\$326,219,409.00	29.7%	\$1,098,631,000.00
NIH	\$448,138,300.00	1.5%	\$30,860,913,000.00

<http://report.nih.gov/rcdc/>


International Alzheimer's Disease Research Portfolio (IADRP)

- Developed by NIA in collaboration with Alzheimer's Association - <http://iadrp.nia.nih.gov/cadro-web/>
- Will enable funders of Alzheimer's research to coordinate planning, leverage resources, avoid duplication, and identify new opportunities for collaboration.
- Will give the public a full picture of the scale of ongoing research on AD.
- To date, includes only Federally funded and Alzheimer's Association-supported projects. Efforts are underway to include more domestic and international funders.
- Data Sharing Agreements with Alzheimer's Research UK (data to be uploaded later this month)

Category C.

Translational Research and Clinical Interventions

Investment Trends in Amyloid and Non-Amyloid Therapeutic Targets



AD Projects Funded through White House Initiative 2012 - 1

- **Whole genome/exome sequencing** to identify new genetic variants that either increase risk (risk factors) or reduce risk (protective factors) of AD.
- **Prevention trial** to test the ability of an antibody called crenezumab to bind to and clear away abnormal amounts of amyloid protein in the brains of people who are PS1 mutation carriers.
- **Treatment trial** of intranasal insulin vs. placebo in individuals with MCI or mild Alzheimer's dementia to compare cognition, memory, and functional performance.

AD Projects Funded through White House Initiative 2012 - 2

- Use of new induced pluripotent stem (iPS) cell methods to obtain insights into the cellular processes of Alzheimer's.
- Support to the Atherosclerosis Risk in Communities (ARIC) Neurocognitive study (ARIC-NCS) focused on prediction of cognitive impairment from mid-life vascular risk factors and markers.
- Small business grants for Alzheimer's disease research.

White House Proposal for \$80 Million Additional AD Funding in FY 2013

NIH is using the following process to ensure timely and most effective spending of the anticipated \$80M in additional funding for AD research for the current fiscal year:

- Representatives from several NIH ICs worked together to identify areas of highest need/opportunity, informed by the Alzheimer's Summit and other input.
- NIA took the lead on developing FOA concepts for presentation at NACA in September 2012.
- Extra funding will allow NIH to support more grants through these or existing FOAs and/or investigator-initiated research.

FY 2013 AD Concept Clearance

- Drug Discovery Training for Academic Scientists
- Preclinical Testing Data Repository
- Preclinical Animal Model Testing

FY 2013 AD Concept Clearance

- Genetic Analysis
- Target Identification and Validation
- Phase I Clinical Trials for AD Therapeutics
- Prevention Trials

**Special Thanks to Dr. Steve Snyder
Acting Director, Division of Neuroscience**



NIA Announces New Director, Division of Neuroscience



Neil S. Buckholtz, Ph.D.